BioLife Solutions, Inc. (NASDAQ:BLFS) VP Marcus Schulz sold 953 shares of the company’s stock in a transaction on Monday, October 12th. The shares were sold at an average price of $28.20, for a total transaction of $26,874.60. Following the completion of the sale, the vice president now directly owns 41,753 shares of the company’s stock, valued at approximately $1,177,434.60. The sale was disclosed in a filing with the SEC, which is accessible through this link.
NASDAQ:BLFS opened at $28.17 on Friday. The company has a fifty day moving average of $25.81 and a 200 day moving average of $18.35. BioLife Solutions, Inc. has a 52 week low of $7.37 and a 52 week high of $30.27. The firm has a market capitalization of $901.50 million, a P/E ratio of -88.03, a P/E/G ratio of 93.77 and a beta of 1.44.
BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported ($0.01) EPS for the quarter. BioLife Solutions had a return on equity of 1.49% and a net margin of 42.52%. The company had revenue of $9.92 million during the quarter, compared to the consensus estimate of $9.68 million. Research analysts predict that BioLife Solutions, Inc. will post 0.03 EPS for the current fiscal year.
A number of equities research analysts have recently issued reports on the stock. Cowen assumed coverage on shares of BioLife Solutions in a research note on Friday, September 18th. They issued an “outperform” rating and a $33.00 price objective for the company. Maxim Group upped their price objective on shares of BioLife Solutions from $26.00 to $32.00 in a research note on Tuesday, September 22nd. Zacks Investment Research raised shares of BioLife Solutions from a “hold” rating to a “buy” rating and set a $31.00 price objective for the company in a research note on Wednesday. Northland Securities upped their price objective on shares of BioLife Solutions from $27.00 to $35.00 and gave the company an “outperform” rating in a research note on Tuesday, September 22nd. Finally, ValuEngine raised shares of BioLife Solutions from a “hold” rating to a “buy” rating in a research note on Wednesday, August 19th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $28.00.
About BioLife Solutions
BioLife Solutions, Inc develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry in North America, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.